CTNM
Contineum Therapeutics, Inc. · Healthcare · Biotechnology
Last
$15.32
−$0.46 (−2.93%) 4:00 PM ET
Pre-market $15.34 +$0.02 (+0.14%) 5:38 AM ET
Prev close $15.78
Open $15.79
Day high $15.79
Day low $14.92
Volume 211,281
Avg vol 229,567
Mkt cap
$560.36M
P/E ratio
-6.78
EPS
-2.26
Sector
Healthcare
AI report sections
CTNM
Contineum Therapeutics, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
+21% (Above avg)
Vol/Avg: 1.21×
RSI
63.59 (Strong)
Strong (60–70)
MACD momentum
Intraday
+0.02 (Strong)
MACD: 0.05 Signal: 0.03
Short-Term
-0.04 (Weak)
MACD: 0.80 Signal: 0.84
Long-Term
+0.04 (Strong)
MACD: 1.33 Signal: 1.29
Intraday trend score 56.00

Latest news

CTNM 6 articles Positive: 1 Neutral: 2 Negative: 0
Neutral The Motley Fool • Jesterai
Contineum (CTNM) Q2 R&D Jumps 78%

Contineum Therapeutics reported a wider Q2 2025 net loss of $0.62 per share, driven by increased R&D expenses. The company continues developing treatments for pulmonary fibrosis, multiple sclerosis, and depression, with ongoing clinical trials for PIPE-791 and PIPE-307.

CTNM JNJ biotechnology clinical trials R&D drug development pulmonary fibrosis multiple sclerosis
Sentiment note

Despite wider net loss, the company maintains a strong cash position of $175.5 million, continues advancing clinical pipeline, and has strategic partnerships with Johnson & Johnson. Ongoing R&D investments and delayed trials suggest cautious progress.

Positive GlobeNewswire Inc. • Delveinsight
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The pulmonary fibrosis market is driven by the increasing prevalence of the disease, especially idiopathic pulmonary fibrosis, among the aging population. Innovations in drug development and diagnostics, favorable reimbursement policies, and greater awareness are fueling market growth. The pipeline appears robust with over 110 active players working on 120+ pipeline drugs.

SNDX PRTC OTSKY TRVI pulmonary fibrosis idiopathic pulmonary fibrosis drug development diagnostics
Sentiment note

Contineum Therapeutics is one of the key companies actively working on the pulmonary fibrosis pipeline, indicating a strong focus on addressing the unmet needs in this therapeutic area.

Neutral GlobeNewswire Inc. • Rapt Therapeutics, Inc.
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment of Lori Lyons-Williams as the new chair of its board of directors, succeeding William Rieflin. Lyons-Williams is an industry veteran with over 20 years of experience in the pharmaceutical and biotech sectors.

RAPT CTNM RAPT Therapeutics Lori Lyons-Williams William Rieflin board of directors biopharmaceutical company inflammatory diseases
Sentiment note

The article briefly mentions that Lori Lyons-Williams serves on the board of directors of Contineum Therapeutics, but does not provide any further details about the company, so a neutral sentiment is assigned.

Unknown Seeking Alpha • Wall Street Breakfast
Wall Street Breakfast: The Week Ahead

This article discusses the upcoming events in the financial world, including the Federal Reserve meeting, corporate earnings, IPOs, and investor events.

COP PFE KO MCD
Unknown Benzinga • Avi Kapoor
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. Skillsoft posted adjusted loss of $3.09 per share, versus market estimates of $3.27 per share. The company’s quarterly sales came in at $137.540 million versus expectations of $141.897 million. Skillsoft shares dipped 26.7% to $6.74 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers WiSA Technologies, Inc. (NASDAQ: WISA) jumped 85% to $3.2379 after the company announced a 5-year WiSA E licensing agreement with an HDTV/PTV brand. Palisade Bio, Inc. (NASDAQ: PALI) shares climbed 79.1% to $7.45 after the company announced the completion of analysis evaluating ex-vivo bioactivation of PALI-2108. Jaguar Health, Inc. (NASDAQ: JAGX) shares gained 67% to $0.1989 after the company signed an exclusive 5-year in-license agreement with Venture Life Group for Gelclair. Dynatronics Corporation (NASDAQ: DYNT) shares rose 44.4% to $0.5342 after dipping over 5% on Monday. IMAC Holdings, Inc. (NASDAQ: BACK) surged 40% to $4.69. Peraso Inc. (NASDAQ: PRSO) gained 38.8% to $1.75. Peraso recently announced that it received an additional $2.88 million purchase order. Macatawa Bank Corporation (NASDAQ: MCBC) rose 38.8% to $13.78 after Wintrust Financial Corporation (NASDAQ: WFTC) and Macatawa Bank announced that they have entered into a definitive merger agreement for Wintrust to acquire Macatawa in an all-stock transaction. China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) jumped 29.9% to ...

BNED NN NXL PRSO News Penny Stocks Small Cap Intraday Update
Unknown Benzinga • Avi Kapoor
UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday. Shares of UnitedHealth Group Incorporated (NYSE: UNH) rose sharply during Tuesday’s session following better-than-expected first-quarter earnings. The company reported adjusted EPS of $6.91, up from $6.26 a year ago, beating the consensus of $6.62. UnitedHealth’s revenues increased nearly $8 billion to $99.8 billion, beating the consensus of $99.3 billion, according to data from Benzinga Pro. UnitedHealth Group shares surged 6.2% to $473.20 on Tuesday. Here are some other big stocks recording losses in today’s session. Macatawa Bank Corporation (NASDAQ: MCBC) ...

ERIC MCBC SMCI GB News Small Cap Intraday Update Markets
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal